Physician profile
Derek Skinner
NPI 1255394920
$1,357.11
in general payments reported to CMS, 2019-2025
31 companies · $19.84 in 2025
The $19.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $144 · 2022: $61.20 · 2023: $38.16 · 2024: $21.75 · 2025: $19.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $185.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $120.73 | 2019-2020 | |
| Pfizer INC. | $119.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $112.03 | 2022-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $84.02 | 2019-2020 | |
| Amgen INC. | $65.68 | 2019-2020 | |
| Shire North American Group INC | $58.71 | 2019 | |
| Mylan Specialty L.P. | $56.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.63 | 2019 | |
| Novo Nordisk INC | $48.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.99 | 2019 | |
| Depuy Synthes Sales INC. | $38.01 | 2019 | |
| Eisai INC. | $32.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.33 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.80 | 2019-2020 | |
| Aytu Biopharma, INC. | $26.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.71 | 2019 | |
| Lilly USA, LLC | $21.91 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.99 | 2019 | |
| Melinta Therapeutics, LLC | $15.83 | 2019 | |
| Redhill Biopharma INC. | $15.82 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.69 | 2022 | |
| Merck Sharp & Dohme LLC | $14.71 | 2019 | |
| Pacira Therapeutics, INC. | $14.69 | 2019 | |
| Radius Health, INC. | $14.15 | 2019 | |
| Astellas Pharma US INC | $14.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.09 | 2019 | |
| Amarin Pharma, INC. | $13.30 | 2019 | |
| Urovant Sciences INC | $13.23 | 2022 | |
| Assertio Therapeutics, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.